Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gatipotuzumab maintenance in recurrent ovarian cancer
NCT01899599Phase 2Completed
- Sponsor
- Glycotope
- Start
- Sep 2013
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of Gatipotuzumab in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Glycotope. Started Sep 2013; status: completed.
02
Drugs
Gatipotuzumab
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01899599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01899599.